315 related articles for article (PubMed ID: 19638503)
21. [New era in cancer therapy. Gefitinib: small molecule--strong action].
Arnheim K
MMW Fortschr Med; 2004 Nov; 146(47):70-1. PubMed ID: 15624666
[No Abstract] [Full Text] [Related]
22. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Jänne PA; Johnson BE
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
[TBL] [Abstract][Full Text] [Related]
23. [Personalized treatment in non-small cell lung cancer].
Campos-Parra AD; Cruz-Rico G; Arrieta O
Rev Invest Clin; 2012; 64(4):377-86. PubMed ID: 23227588
[No Abstract] [Full Text] [Related]
24. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
Uramoto H; Yamada T; Yano S; Kondo N; Hasegawa S; Tanaka F
Anticancer Res; 2012 Sep; 32(9):3785-90. PubMed ID: 22993320
[TBL] [Abstract][Full Text] [Related]
25. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
Sequist LV; Bell DW; Lynch TJ; Haber DA
J Clin Oncol; 2007 Feb; 25(5):587-95. PubMed ID: 17290067
[TBL] [Abstract][Full Text] [Related]
26. Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.
Kotsakis A; Georgoulias V
Expert Opin Pharmacother; 2010 Oct; 11(14):2363-89. PubMed ID: 20586711
[TBL] [Abstract][Full Text] [Related]
27. EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer.
Miller VA
Semin Oncol Nurs; 2008 Feb; 24(1):27-33. PubMed ID: 18222149
[TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.
Pao W; Miller VA
J Clin Oncol; 2005 Apr; 23(11):2556-68. PubMed ID: 15767641
[TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ
Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670
[TBL] [Abstract][Full Text] [Related]
30. EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy.
Irmer D; Funk JO; Blaukat A
Oncogene; 2007 Aug; 26(39):5693-701. PubMed ID: 17353898
[TBL] [Abstract][Full Text] [Related]
31. More than just an oncogene translocation and a kinase inhibitor: Kevin's story.
Costa DB
J Clin Oncol; 2012 Jan; 30(1):110-2. PubMed ID: 22067391
[No Abstract] [Full Text] [Related]
32. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
Comis RL
Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313
[No Abstract] [Full Text] [Related]
33. EGFR inhibition in NSCLC: the emerging role of cetuximab.
Herbst RS
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S41-51. PubMed ID: 19780245
[TBL] [Abstract][Full Text] [Related]
34. Pharmacogenomics. Cancer sharpshooters rely on DNA tests for a better aim.
Couzin J
Science; 2004 Aug; 305(5688):1222-3. PubMed ID: 15333809
[No Abstract] [Full Text] [Related]
35. The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy.
Dowell JE; Minna JD
Nat Clin Pract Oncol; 2004 Nov; 1(1):2-3. PubMed ID: 16264773
[No Abstract] [Full Text] [Related]
36. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.
Jackman DM; Holmes AJ; Lindeman N; Wen PY; Kesari S; Borras AM; Bailey C; de Jong F; Jänne PA; Johnson BE
J Clin Oncol; 2006 Sep; 24(27):4517-20. PubMed ID: 16983123
[No Abstract] [Full Text] [Related]
37. Flipped script for gefitinib: A reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer.
Bogdanowicz BS; Hoch MA; Hartranft ME
J Oncol Pharm Pract; 2017 Apr; 23(3):203-214. PubMed ID: 26911477
[TBL] [Abstract][Full Text] [Related]
38. Afatinib (Gilotrif) for advanced non-small cell lung cancer.
Med Lett Drugs Ther; 2015 May; 57(1469):e82-3. PubMed ID: 26039556
[No Abstract] [Full Text] [Related]
39. Medicine. Why a new cancer drug works well, in some patients.
Marx J
Science; 2004 Apr; 304(5671):658-9. PubMed ID: 15118127
[No Abstract] [Full Text] [Related]
40. Lung cancer: looking ahead in 2004.
Belani CP; Ramalingam S
Clin Lung Cancer; 2004 Jan; 5(4):200. PubMed ID: 14967070
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
